Osimertinib: Evolution of Treatment from Refractory Disease to Prevention of Drivers of Disease Progression
Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, are now being used proactively to prevent drivers of disease progression.
Video content above is prompted by the following:
- Agents such as osimertinib that first targeted resistance mechanisms in refractory disease are now being used to prevent drivers of disease progression.
- Please discuss your thoughts about this strategy.
Recent Videos
